Nov 14, 2023 7:30am EST QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Aug 16, 2023 8:00am EDT QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
Jun 14, 2023 8:00am EDT QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
May 23, 2023 8:00am EDT QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center
May 16, 2023 8:30am EDT QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
Apr 26, 2023 8:00am EDT QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
Apr 05, 2023 8:00am EDT QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
Mar 20, 2023 8:30am EDT QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
Mar 08, 2023 8:00am EST QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
Feb 28, 2023 8:00am EST QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
